NDA 21136, held by Chirhoclin. Secretin Synthetic Porcine.
As of Nov 15, 2026, NDA 21136 (Secreflo), held by Chirhoclin, was first approved by FDA on Apr 4, 2002, with 7 approved supplements and 0 published complete response letters.
| Nov 1, 2002 | Supplement 1Efficacy (new indication or use) · Priority review | Approved | |
| Apr 4, 2002 | Original applicationNew dosage form · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Secreflo16MCG/VIAL · for solution;intravenous | Secretin Synthetic Porcine | Discontinued |
| Oct 26, 2016 | Supplement 12Labeling · Standard review | Approved | |
| Oct 26, 2016 | Supplement 13Labeling · Standard review | Approved | |
| Sep 12, 2005 | Supplement 11Labeling · Standard review | Approved | |
| Jul 26, 2004 | Supplement 9Labeling · Standard review | Approved | |
| Mar 1, 2004 | Supplement 5Manufacturing · Standard review | Approved | |
| Mar 1, 2004 | Supplement 6Manufacturing · Standard review | Approved | |
| Nov 1, 2002 | Supplement 1Efficacy (new indication or use) · Priority review | Approved | |
| Apr 4, 2002 | Original applicationNew dosage form · Standard review | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
